Get the Stockscreener App
0.405
1.00%
0.00401
Entero Therapeutics Inc stock is traded at $0.405, with a volume of 13,418.
It is up +1.00% in the last 24 hours and down -40.44% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.401
Open:
$0.398
24h Volume:
13,418
Relative Volume:
0.03
Market Cap:
$1.90M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-22.32%
1M Performance:
-40.44%
6M Performance:
-85.84%
1Y Performance:
+0.00%
1-Day Range:
$0.398
$0.42
1-Week Range:
$0.38
$0.5015
52-Week Range:
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ENTO | 0.40 | 1.90M | 0 | 0 | 0 | 0.00 |
| VRTX | 448.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.12 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.32 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.27 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Entero Therapeutics Inc Stock (ENTO) Latest News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada
Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com
FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register
Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India
Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex
Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News
Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily
Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News
ENTO’s 2023 Market Dance: Down -85.72% – Time to Invest? - The InvestChronicle
Lexicon Pharmaceuticals (LXRX) Stock Surges Amid Positive Analys - GuruFocus.com
EMCOR Group (NYSE:EME) Sets New 12-Month High at $402.91 - Defense World
Evolus (NASDAQ:EOLS) Trading Down 2.9% - Defense World
Health Beat: Hope for children with EoE - 69News WFMZ-TV
Emmaus Life Sciences director buys $800 in company stock By Investing.com - Investing.com UK
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
EMCOR Group (NYSE:EME) Hits New 1-Year High at $402.91 - MarketBeat
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics faces Nasdaq delisting over share price - Investing.com
Entero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Canoo Inc (NASDAQ: GOEV) Could Pass $4.5 In One Year Stock Forecast - Stocks Register
Understanding ENTO stock ratios for better investment decisions - US Post News
Entero Therapeutics Secures Exclusive Technology License - Investing.com
Entero Therapeutics Secures Exclusive Technology License By Investing.com - Investing.com Canada
Entero Therapeutics signs letter of intent with Data Vault Holdings - TipRanks
Entero Therapeutics Signs Letter of Intent to License and - GlobeNewswire
Entero Therapeutics appoints new independent accountant - Investing.com India
Entero Therapeutics appoints new independent accountant By Investing.com - Investing.com Canada
Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 666.0% in August - Defense World
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewswire
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):